ISO 10993-4
What Is ISO 10993-4?
ISO 10993-4 is part of the ISO 10993 series of standards for biological evaluation of medical devices. It addresses the selection of tests for interactions with blood and is commonly referenced when evaluating blood-contacting medical devices.
For companies developing vascular implants, catheters, grafts, filters, and other blood-contacting technologies, ISO 10993-4 can help guide hemocompatibility test planning. The standard does not provide a single universal test for every device. Instead, it supports a risk-based approach to selecting appropriate evaluations based on device type, blood contact category, duration of contact, and intended clinical use.
Why ISO 10993-4 Matters
Blood-contacting devices can interact with coagulation pathways, platelets, red blood cells, white blood cells, plasma proteins, and complement pathways. These interactions may affect device performance, biological safety, or development risk.
ISO 10993-4 helps development teams consider which blood interaction endpoints may be relevant for a given device. This can include thrombosis, coagulation, platelet effects, hematology, hemolysis, and complement-related endpoints.
Device-Specific Test Planning
A key concept in ISO 10993-4 evaluation is that test planning should be device-specific. The biological evaluation strategy for a long-term vascular implant may differ from that of a short-term catheter, extracorporeal device, blood filter, or transiently used delivery system.
Factors that may influence test selection include:
Direct or indirect blood contact
Duration of blood contact
Circulating vs. static blood exposure
Implantable vs. external communicating device
Device geometry and surface area
Materials of construction
Coatings or surface modifications
Anticoagulation conditions during intended use
Flow conditions and shear environment
Clinical risk profile
Hemocompatibility Endpoints
Depending on the device, hemocompatibility evaluation may include endpoints related to:
Thrombosis
Assessment of clot or thrombus formation on or around the device surface.
Coagulation
Evaluation of coagulation pathway activation or clotting-related markers.
Platelets
Assessment of platelet adhesion, activation, consumption, or morphology.
Hematology
Measurement of blood cell counts or changes after device exposure.
Hemolysis
Evaluation of red blood cell damage and plasma-free hemoglobin.
Complement activation
Assessment of immune-related blood protein activation, where relevant.
ISO 10993-4 and Coated Devices
For coated blood-contacting devices, hemocompatibility testing may need to evaluate the finished device surface, not just the base material. Coatings can change the outermost surface chemistry and may influence blood interaction results. Test articles should be representative of the final device design and manufacturing process whenever possible.
Coating development programs may compare coated and uncoated devices under controlled conditions to understand how the coating affects thrombosis, platelet response, hemolysis, or other relevant endpoints.
How Alta Biomed Supports ISO 10993-4-Aligned Testing
Alta Biomed provides hemocompatibility testing support for blood-contacting medical devices, including dynamic blood loop testing and comparative testing of coated and uncoated devices. Our work can support early feasibility, coating development, and test strategy discussions for ISO 10993-4-aligned biological evaluation programs.
Developing a Blood Contacting Device?
Contact Alta Biomed to discuss ISO 10993-4-aligned hemocompatibility testing support.
6070 Corte Del Cedro, Unit A
Carlsbad, CA 92011